Vaxcyte Inc. Common Stock vs First Trust NASDAQ Clean Edge Green Energy Idx Fd — how do they compare? Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B), while First Trust NASDAQ Clean Edge Green Energy Idx Fd trades at $44.72 (market cap $524.91M). The key difference: Vaxcyte Inc. Common Stock is far larger — about 20× First Trust NASDAQ Clean Edge Green Energy Idx Fd's market cap, and Vaxcyte Inc. Common Stock is trading nearer its 52-week high, First Trust NASDAQ Clean Edge Green Energy Idx Fd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Vaxcyte Inc. Common Stock for 0 Days and First Trust NASDAQ Clean Edge Green Energy Idx Fd for 52 Days on average.
| PCVX | QCLN | |
|---|---|---|
Market Cap | $10.51B | $524.91M |
Volume | 2,644,694 | 261,814 |
Sector | Health | Sector/Thematic |
52-Week High | $73.82 | $68.47 |
52-Week Low | $40.32 | $41.10 |
Typical Hold Time | 0 Days | 52 Days |
Enterprise Value | $9.14B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
QCLN trades at $47.24, showing minimal daily movement with a 0.25% gain. Technical indicators signal bearish momentum as the stock trades below key moving averages, though oversold RSI conditions suggest potential near-term support. Recent news highlights the ETF's sensitivity to political outcomes and global energy transitions, with geopolitical tensions driving renewed interest in clean energy investments.
The fund's performance remains heavily dependent on policy developments and energy market dynamics. While global renewable energy acceleration provides long-term tailwinds, near-term volatility persists due to political uncertainty and technical weakness. Investors face balanced risk-reward with policy catalysts potentially offsetting current bearish technical signals.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →QCLN invests in U.S.-listed companies engaged in clean energy technologies. It focuses on solar power, wind, electric vehicles, and energy storage, with major holdings in firms like Tesla, ON Semiconductor, and Rivian.
Read more on QCLN →